Israel's Teva Pharmaceutical Industries was celebrated for its impressive growth and management style in a detailed report submitted by Standard & Poor's Equity Research and published by Business Week magazine.
The report listed Teva's many accomplishments in the US market, including commanding an 11.4 percent share of all branded and generic drug prescriptions filled, making it the largest pharmaceutical company in America.
Teva's massive growth has been attributed to its low-cost production of active pharmaceutical ingredient (API), enabling it to offer a wide range of generic label drugs at deeply discounted prices.
Standard & Poor's expects Teva's 2007 revenue to top $9.5 billion, a 12.5 percent increase from 2006. The following year looks even brighter, with a forecast revenue increase of 13.3 percent to $10.7 billion in 2008.